Treatment of shiga toxin-producing escherichia coli infections

Infectious Disease Clinics of North America

Volumn 27, Issue 3, 2013, Pages 577-597

  Davis, T Keefe ^a   McKee, Ryan ^a   Schnadower, David ^a   Tarr, Phillip I ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotics; Escherichia coli O157:H7; Hemolytic uremic syndrome; Microbiologic diagnosis; Shiga toxin

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; ECULIZUMAB; VEROTOXIN;

BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; BACTERIUM COLONY; BLOODY DIARRHEA; CLOSTRIDIUM DIFFICILE INFECTION; DIARRHEA; ENTEROHEMORRHAGIC ESCHERICHIA COLI; EPIDEMIC; ESCHERICHIA COLI INFECTION; ESCHERICHIA COLI O157; FECES ANALYSIS; FEVER; HEMOLYTIC UREMIC SYNDROME; HUMAN; INTERVENTION STUDY; KIDNEY FAILURE; LABORATORY TEST; NONHUMAN; PATHOGENESIS; PERITONEAL DIALYSIS; PERITONITIS; PREVALENCE; REVIEW; RISK FACTOR; SEPTIC SHOCK; SEROLOGY; SEROTYPE; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; SYMPTOMATOLOGY; THROMBOCYTOPENIA; URINALYSIS;

ANTIBIOTICS; ESCHERICHIA COLI O157:H7; HEMOLYTIC UREMIC SYNDROME; MICROBIOLOGIC DIAGNOSIS; SHIGA-TOXIN;

ANTI-BACTERIAL AGENTS; ESCHERICHIA COLI INFECTIONS; FLUID THERAPY; HEMOLYTIC-UREMIC SYNDROME; HUMANS; ISOTONIC SOLUTIONS; SHIGA-TOXIGENIC ESCHERICHIA COLI;

EID: 84883558575     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2013.05.010     Document Type: Review

References (100)

1. Denno D.M., Shaikh N., Stapp J.R., et al. Diarrhea etiology in a pediatric emergency department: a case control study. Clin Infect Dis 2012, 55(7):897-904.
2. Watanabe H., Terajima J., Izumiya H., et al. Molecular analysis of enterohemorrhagic Escherichia coli isolates in Japan and its application to epidemiological investigation. Pediatr Int 1999, 41(2):202-208.
3. Stephan R., Untermann F. Virulence factors and phenotypical traits of verotoxin-producing Escherichia coli strains isolated from asymptomatic human carriers. JClin Microbiol 1999, 37(5):1570-1572.
4. Tarr P.I., Gordon C.A., Chandler W.L. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005, 365(9464):1073-1086.
5. Lopez E.L., Contrini M.M., Glatstein E., et al. An epidemiologic surveillance of Shiga-like toxin-producing Escherichia coli infection in Argentinean children: risk factors and serum Shiga-like toxin 2 values. Pediatr Infect Dis J 2012, 31(1):20-24.
6. Chandler W.L., Jelacic S., Boster D.R., et al. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. NEngl J Med 2002, 346(1):23-32.
7. Tsai H.M., Chandler W.L., Sarode R., et al. Von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome. Pediatr Res 2001, 49(5):653-659.
8. Bitzan M., Mellnann A., Karch H., et al. Shigatec: A phase II study evaluating shigamabs in STEC-infected children. Zoonoses and Public Health 2012, 59(Suppl 1):2-18.
9. Neill M.A., Tarr P.I., Clausen C.R., et al. Escherichia coli O157:H7 as the predominant pathogen associated with the hemolytic uremic syndrome: a prospective study in the Pacific Northwest. Pediatrics 1987, 80(1):37-40.
10. Tarr P.I., Neill M.A., Clausen C.R., et al. Escherichia coli O157:H7 and the hemolytic uremic syndrome: importance of early cultures in establishing the etiology. JInfect Dis 1990, 162(2):553-556.
11. Rowe P.C., Orrbine E., Lior H., et al. Risk of hemolytic uremic syndrome after sporadic Escherichia coli O157:H7 infection: results of a Canadian collaborative study. Investigators of the Canadian Pediatric Kidney Disease Research Center. JPediatr 1998, 132(5):777-782.
12. Miceli S., Jure M.A., de Saab O.A., et al. Aclinical and bacteriological study of children suffering from haemolytic uraemic syndrome in Tucuman, Argentina. Jpn J Infect Dis 1999, 52(2):33-37.
13. Banatvala N., Griffin P.M., Greene K.D., et al. The United States National Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, clinical, and epidemiologic findings. JInfect Dis 2001, 183(7):1063-1070.
14. Klein E.J., Stapp J.R., Clausen C.R., et al. Shiga toxin-producing Escherichia coli in children with diarrhea: a prospective point-of-care study. JPediatr 2002, 141(2):172-177.
15. Rivas M., Miliwebsky E., Chinen I., et al. Characterization and epidemiologic subtyping of Shiga toxin-producing Escherichia coli strains isolated from hemolytic uremic syndrome and diarrhea cases in Argentina. Foodborne Pathog Dis 2006, 3(1):88-96.
16. Pollock K.G., Young D., Beattie T.J., et al. Clinical surveillance of thrombotic microangiopathies in Scotland, 2003-2005. Epidemiol Infect 2008, 136(1):115-121.
17. Hickey C.A., Beattie T.J., Cowieson J., et al. Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome. Arch Pediatr Adolesc Med 2011, 165(10):884-889.
18. Hadler J.L., Clogher P., Hurd S., et al. Ten-year trends and risk factors for non-O157 Shiga toxin-producing Escherichia coli found through Shiga toxin testing, Connecticut, 2000-2009. Clin Infect Dis 2011, 53(3):269-276.
19. Mody R.K., Luna-Gierke R.E., Jones T.F., et al. Infections in pediatric postdiarrheal hemolytic uremic syndrome: factors associated with identifying Shiga toxin-producing Escherichia coli. Arch Pediatr Adolesc Med 2012, 166(10):902-909.
20. Leopold S.R., Magrini V., Holt N.J., et al. Aprecise reconstruction of the emergence and constrained radiations of Escherichia coli O157 portrayed by backbone concatenomic analysis. Proc Natl Acad Sci USA 2009, 106(21):8713-8718.
21. Chapman P.A., Siddons C.A. Acomparison of immunomagnetic separation and direct culture for the isolation of verocytotoxin-producing Escherichia coli O157 from cases of bloody diarrhoea, non-bloody diarrhoea and asymptomatic contacts. JMed Microbiol 1996, 44(4):267-271.
22. Fey P.D., Wickert R.S., Rupp M.E., et al. Prevalence of non-O157:H7 Shiga toxin-producing Escherichia coli in diarrheal stool samples from Nebraska. Emerg Infect Dis 2000, 6(5):530-533.
23. Carroll K.C., Adamson K., Korgenski K., et al. Comparison of a commercial reversed passive latex agglutination assay to an enzyme immunoassay for the detection of Shiga toxin-producing Escherichia coli. Eur J Clin Microbiol Infect Dis 2003, 22(11):689-692.
24. Manning S.D., Madera R.T., Schneider W., et al. Surveillance for Shiga toxin-producing Escherichia coli, Michigan, 2001-2005. Emerg Infect Dis 2007, 13(2):318-321.
25. Teel L.D., Daly J.A., Jerris R.C., et al. Rapid detection of Shiga toxin-producing Escherichia coli by optical immunoassay. JClin Microbiol 2007, 45(10):3377-3380.
26. Park C.H., Kim H.J., Hixon D.L., et al. Evaluation of the duopath verotoxin test for detection of Shiga toxins in cultures of human stools. JClin Microbiol 2003, 41(6):2650-2653.
27. Gould L.H., Bopp C., Strockbine N., et al. Recommendations for diagnosis of Shiga toxin-producing Escherichia coli infections by clinical laboratories. MMWR Recomm Rep 2009, 58(RR-12):1-14.
28. Bielaszewska M., Mellmann A., Zhang W., et al. Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study. Lancet Infect Dis 2011, 11(9):671-676.
29. Buchholz U., Bernard H., Werber D., et al. German outbreak of Escherichia coli o104:H4 associated with sprouts. NEngl J Med 2011, 365(19):1763-1770.
30. Klein E.J., Boster D.R., Stapp J.R., et al. Diarrhea etiology in a children's hospital emergency department: a prospective cohort study. Clin Infect Dis 2006, 43(7):807-813.
31. Bokete T.N., O'Callahan C.M., Clausen C.R., et al. Shiga-like toxin-producing Escherichia coli in Seattle children: a prospective study. Gastroenterology 1993, 105(6):1724-1731.
32. Jelacic J.K., Damrow T., Chen G.S., et al. Shiga toxin-producing Escherichia coli in Montana: bacterial genotypes and clinical profiles. JInfect Dis 2003, 188(5):719-729.
33. Holtz L.R., Neill M.A., Tarr P.I. Acute bloody diarrhea: a medical emergency for patients of all ages. Gastroenterology 2009, 136(6):1887-1898.
34. Wong C.S., Mooney J.C., Brandt J.R., et al. Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin Infect Dis 2012, 55(1):33-41.
35. Ake J.A., Jelacic S., Ciol M.A., et al. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Pediatrics 2005, 115(6):e673-e680.
36. Smith J.M., Jones F., Ciol M.A., et al. Platelet-activating factor and Escherichia coli O157:H7 infections. Pediatr Nephrol 2002, 17(12):1047-1052.
37. Cornick N.A., Jelacic S., Ciol M.A., et al. Escherichia coli O157:H7 infections: discordance between filterable fecal Shiga toxin and disease outcome. JInfect Dis 2002, 186(1):57-63.
38. Wong C.S., Jelacic S., Habeeb R.L., et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. NEngl J Med 2000, 342(26):1930-1936.
39. Carter A.O., Borczyk A.A., Carlson J.A., et al. Asevere outbreak of Escherichia coli O157:H7-associated hemorrhagic colitis in a nursing home. NEngl J Med 1987, 317(24):1496-1500.
40. Dundas S., Todd W.T., Stewart A.I., et al. The Central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin Infect Dis 2001, 33(7):923-931.
41. Bell B.P., Goldoft M., Griffin P.M., et al. Amultistate outbreak of Escherichia coli O157:H7-associated bloody diarrhea and hemolytic uremic syndrome from hamburgers. The Washington experience. JAMA 1994, 272(17):1349-1353.
42. Moritz M.L., Ayus J.C. Improving intravenous fluid therapy in children with gastroenteritis. Pediatr Nephrol 2010, 25(8):1383-1384.
43. Hanna M., Saberi M.S. Incidence of hyponatremia in children with gastroenteritis treated with hypotonic intravenous fluids. Pediatr Nephrol 2010, 25(8):1471-1475.
44. Balestracci A., Martin S.M., Toledo I., et al. Dehydration at admission increased the need for dialysis in hemolytic uremic syndrome children. Pediatr Nephrol 2012, 27(8):1407-1410.
45. Coad N.A., Marshall T., Rowe B., et al. Changes in the postenteropathic form of the hemolytic uremic syndrome in children. Clin Nephrol 1991, 35(1):10-16.
46. Oakes R.S., Siegler R.L., McReynolds M.A., et al. Predictors of fatality in postdiarrheal hemolytic uremic syndrome. Pediatrics 2006, 117(5):1656-1662.
47. Gianantonio C.A., Vitacco M., Mendilaharzu F., et al. The hemolytic-uremic syndrome. Nephron 1973, 11(2):174-192.
48. Oakes R.S., Kirkham J.K., Nelson R.D., et al. Duration of oliguria and anuria as predictors of chronic renal-related sequelae in post-diarrheal hemolytic uremic syndrome. Pediatr Nephrol 2008, 23(8):1303-1308.
49. Loirat C. Post-diarrhea hemolytic-uremic syndrome: clinical aspects. Arch Pediatr 2001, 8(Suppl 4):776s-784s. [in French].
50. Siegler R.L., Pavia A.T., Christofferson R.D., et al. A20-year population-based study of postdiarrheal hemolytic uremic syndrome in Utah. Pediatrics 1994, 94(1):35-40.
51. Siegler R.L., Milligan M.K., Burningham T.H., et al. Long-term outcome and prognostic indicators in the hemolytic-uremic syndrome. JPediatr 1991, 118(2):195-200.
52. Garg A.X., Suri R.S., Barrowman N., et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA 2003, 290(10):1360-1370.
53. Tonshoff B., Sammet A., Sanden I., et al. Outcome and prognostic determinants in the hemolytic uremic syndrome of children. Nephron 1994, 68(1):63-70.
54. Huseman D., Gellermann J., Vollmer I., et al. Long-term prognosis of hemolytic uremic syndrome and effective renal plasma flow. Pediatr Nephrol 1999, 13(8):672-677.
55. Mizusawa Y., Pitcher L.A., Burke J.R., et al. Survey of haemolytic-uraemic syndrome in Queensland 1979-1995. Med J Aust 1996, 165(4):188-191.
56. Spizzirri F.D., Rahman R.C., Bibiloni N., et al. Childhood hemolytic uremic syndrome in Argentina: long-term follow-up and prognostic features. Pediatr Nephrol 1997, 11(2):156-160.
57. Gianantonio C.A., Vitacco M., Mendilaharzu F., et al. The hemolytic-uremic syndrome. Renal status of 76 patients at long-term follow-up. JPediatr 1968, 72(6):757-765.
58. Dolislager D., Tune B. The hemolytic-uremic syndrome: spectrum of severity and significance of prodrome. Am J Dis Child 1978, 132(1):55-58.
59. de Jong M.C., Monnens L.A. Recurrent haemolytic uraemic syndrome. Padiatr Padol 1976, 11(3):521-527.
60. Mencia Bartolome S., Martinez de Azagra A., de Vicente Aymat A., et al. Uremic hemolytic syndrome. Analysis of 43 cases. An Esp Pediatr 1999, 50(5):467-470. [in Spanish].
61. Tarr P.I. Shiga toxin-associated hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: distinct mechanisms of pathogenesis. Kidney Int Suppl 2009, 112:S29-S32.
62. Menne J., Nitschke M., Stingele R., et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 2012, 345:e4565.
63. Grisaru S., Morgunov M.A., Samuel S.M., et al. Acute renal replacement therapy in children with diarrhea-associated hemolytic uremic syndrome: a single center 16 years of experience. Int J Nephrol 2011, 2011:930539.
64. Adragna M., Balestracci A., Garcia Chervo L., et al. Acute dialysis-associated peritonitis in children with D+ hemolytic uremic syndrome. Pediatr Nephrol 2012, 27(4):637-642.
65. Warady B.A., Bakkaloglu S., Newland J., et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. Perit Dial Int 2012, 32(Suppl 2):S32-S86.
66. Chadha V., Schaefer F.S., Warady B.A. Dialysis-associated peritonitis in children. Pediatr Nephrol 2010, 25(3):425-440.
67. Burgner D.P., Rfidah H., Beattie T.J., et al. Clostridium difficile after haemolytic uraemic syndrome. Arch Dis Child 1993, 69(2):239-240.
68. Lapeyraque A.L., Malina M., Fremeaux-Bacchi V., et al. Eculizumab in severe Shiga-toxin-associated HUS. NEngl J Med 2011, 364(26):2561-2563.
69. Kielstein J.T., Beutel G., Fleig S., et al. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant 2012, 27(10):3807-3815.
70. Samuelsson O., Follin P., Rundgren M., et al. HUS-epidemin sommaren 2011 var allvarlig. Tyska och svenska erfarenheter av EHEC-utbrottet [The HUS epidemic in the summer of 2011 was severe. German and Swedish experiences of the EHEC outbreak]. Läkartidningen 2012, 109(25):1230-1234. [in Swedish].
71. Nitschke M., Sayk F., Hartel C., et al. Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4. JAMA 2012, 307(10):1046-1052.
72. Seifert M.E., Tarr P.I. Therapy: azithromycin and decolonization after HUS. Nat Rev Nephrol 2012, 8(6):317-318.
73. Ray W.A., Murray K.T., Hall K., et al. Azithromycin and the risk of cardiovascular death. NEngl J Med 2012, 366(20):1881-1890.
74. Seifert M.E., Tarr P.I. Azithromycin decolonization of STEC-a new risk emerges. Nat Rev Nephrol 2012, 8(7):429.
75. Konowalchuk J., Speirs J.I., Stavric S. Vero response to a cytotoxin of Escherichia coli. Infect Immun 1977, 18(3):775-779.
76. Calderwood S., Acheson D.W., Keusch G., et al. Proposed new nomenclature for Shiga-like toxin (verotoxin) family. ASM News 1996, 62:118-119.
77. Calderwood S.B., Auclair F., Donohue-Rolfe A., et al. Nucleotide sequence of the Shiga-like toxin genes of Escherichia coli. Proc Natl Acad Sci USA 1987, 84(13):4364-4368.
78. Levine M.M. Escherichia coli that cause diarrhea: enterotoxigenic, enteropathogenic, enteroinvasive, enterohemorrhagic, and enteroadherent. JInfect Dis 1987, 155(3):377-389.
79. Jarvis K.G., Giron J.A., Jerse A.E., et al. Enteropathogenic Escherichia coli contains a putative type III secretion system necessary for the export of proteins involved in attaching and effacing lesion formation. Proc Natl Acad Sci USA 1995, 92(17):7996-8000.
80. Tango T. Maximum likelihood estimation of date of infection in an outbreak of diarrhea due to contaminated foods assuming lognormal distribution for the incubation period. Nihon Koshu Eisei Zasshi 1998, 45(2):129-141. [in Japanese].
81. Ostroff S.M., Kobayashi J.M., Lewis J.H. Infections with Escherichia coli O157:H7 in Washington state. The first year of statewide disease surveillance. JAMA 1989, 262(3):355-359.
82. Bell B.P., Griffin P.M., Lozano P., et al. Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. Pediatrics 1997, 100(1):E12.
83. Ahn C.K., Holt N.J., Tarr P.I. Shiga-toxin producing Escherichia coli and the hemolytic uremic syndrome: what have we learned in the past 25 years?. Adv Exp Med Biol 2009, 634:1-17.
84. Rodrigue D.C., Mast E.E., Greene K.D., et al. Auniversity outbreak of Escherichia coli O157:H7 infections associated with roast beef and an unusually benign clinical course. JInfect Dis 1995, 172(4):1122-1125.
85. Brandt J.R., Fouser L.S., Watkins S.L., et al. Escherichia coli O157:H7-associated hemolytic-uremic syndrome after ingestion of contaminated hamburgers. JPediatr 1994, 125(4):519-526.
86. Lewis S.J., Heaton K.W. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997, 32(9):920-924.
87. Jelacic S., Wobbe C.L., Boster D.R., et al. ABO and P1 blood group antigen expression and stx genotype and outcome of childhood Escherichia coli O157:H7 infections. JInfect Dis 2002, 185(2):214-219.
88. Thayu M., Chandler W.L., Jelacic S., et al. Cardiac ischemia during hemolytic uremic syndrome. Pediatr Nephrol 2003, 18(3):286-289.
89. Zimmerhackl L.B., Rosales A., Hofer J., et al. Enterohemorrhagic Escherichia coli O26:H11-associated hemolytic uremic syndrome: bacteriology and clinical presentation. Semin Thromb Hemost 2010, 36(6):586-593.
90. Gerber A., Karch H., Allerberger F., et al. Clinical course and the role of Shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study. JInfect Dis 2002, 186(4):493-500.
91. Bielaszewska M., Middendorf B., Kock R., et al. Shiga toxin-negative attaching and effacing Escherichia coli: distinct clinical associations with bacterial phylogeny and virulence traits and inferred in-host pathogen evolution. Clin Infect Dis 2008, 47(2):208-217.
92. Bielaszewska M., Kock R., Friedrich A.W., et al. Shiga toxin-mediated hemolytic uremic syndrome: time to change the diagnostic paradigm?. PLoS One 2007, 2(10):e1024.
93. Friedrich A.W., Zhang W., Bielaszewska M., et al. Prevalence, virulence profiles, and clinical significance of Shiga toxin-negative variants of enterohemorrhagic Escherichia coli O157 infection in humans. Clin Infect Dis 2007, 45(1):39-45.
94. Bielaszewska M., Friedrich A.W., Aldick T., et al. Shiga toxin activatable by intestinal mucus in Escherichia coli isolated from humans: predictor for a severe clinical outcome. Clin Infect Dis 2006, 43(9):1160-1167.
95. Sonntag A.K., Prager R., Bielaszewska M., et al. Phenotypic and genotypic analyses of enterohemorrhagic Escherichia coli o145 strains from patients in Germany. JClin Microbiol 2004, 42(3):954-962.
96. Ikeda K., Ida O., Kimoto K., et al. Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection. Clin Nephrol 1999, 52(6):357-362.
97. Loos S., Ahlenstiel T., Kranz B., et al. An outbreak of Shiga toxin-producing Escherichia coli o104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children. Clin Infect Dis 2012, 55(6):753-759.
98. Proulx F., Turgeon J.P., Delage G., et al. Randomized, controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis. JPediatr 1992, 121(2):299-303.
99. Pavia A.T., Nichols C.R., Green D.P., et al. Hemolytic-uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations. JPediatr 1990, 116(4):544-551.
100. Smith K.E., Wilker P.R., Reiter P.L., et al. Antibiotic treatment of Escherichia coli O157 infection and the risk of hemolytic uremic syndrome, Minnesota. Pediatr Infect Dis J 2012, 31(1):37-41.